Literature DB >> 20602193

Mass screening for gastric cancer: how to select patients for endoscopic examination.

Hirotaka Nakashima1, Ryuji Nagahama, Terushige Yamamoto, Yasuo Ohkura.   

Abstract

BACKGROUND: Gastroendoscopy (GS) has recently been applied in mass screening for gastric cancer, instead of X-ray examination, to improve the quality of the screening. However, as there are currently limitations in the application of endoscopy in all types of screening for gastric cancer, patients must be selected for mass screening by endoscopy. We investigated how to select individuals for endoscopic examination of gastric cancer screening and the effectiveness of X-ray primary screening before endoscopy.
METHODS: All 7942 patients who underwent upper endoscopy for gastric cancer screening at our hospital between April 2005 and March 2008 were divided into two groups: an X-ray screening group (2782 subjects, endoscopy following primary X-ray screening), and a GS direct group (5160 subjects, endoscopy only).
RESULTS: Thirty-seven carcinomas were detected among the 2782 subjects in the X-ray screening group undergoing endoscopy, representing a cancer detection rate of 1.33%. In the GS direct group, 23 carcinomas were detected in the 5160 subjects undergoing endoscopy, representing a cancer detection rate of 0.45%. However, our results suggested that the gastric cancer detection rate by endoscopy was three times higher when it was performed following X-ray screening.
CONCLUSION: There are various conflicting demands for future screening. Our results suggest that it is appropriate to perform an initial X-ray examination followed by endoscopy in prospective screening for gastric cancer.

Entities:  

Mesh:

Year:  2010        PMID: 20602193     DOI: 10.1007/s10120-009-0538-3

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  5 in total

1.  Effectiveness of the small-diameter panendoscope in diagnosing cancers of the upper gastrointestinal tract.

Authors:  M Nishizawa; K Nomoto; T Hosoi; T Okada; K Yamada; T Makino; T Shiga
Journal:  Endoscopy       Date:  1982-01       Impact factor: 10.093

2.  Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers.

Authors:  Takuji Gotoda; Akio Yanagisawa; Mitsuru Sasako; Hiroyuki Ono; Yukihiro Nakanishi; Tadakazu Shimoda; Yo Kato
Journal:  Gastric Cancer       Date:  2000-12       Impact factor: 7.370

3.  Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study.

Authors:  H Watabe; T Mitsushima; Y Yamaji; M Okamoto; R Wada; T Kokubo; H Doi; H Yoshida; T Kawabe; M Omata
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

4.  Japanese Classification of Gastric Carcinoma - 2nd English Edition -

Authors: 
Journal:  Gastric Cancer       Date:  1998-12       Impact factor: 7.370

Review 5.  The Japanese guidelines for gastric cancer screening.

Authors:  Chisato Hamashima; Daisuke Shibuya; Hideo Yamazaki; Kazuhiko Inoue; Akira Fukao; Hiroshi Saito; Tomotaka Sobue
Journal:  Jpn J Clin Oncol       Date:  2008-03-14       Impact factor: 3.019

  5 in total
  3 in total

1.  Does the article, "Mass screening for gastric cancer: how to select patients for endoscopic examination," satisfy criteria of scientific quality?

Authors:  Masao Kobayakawa
Journal:  Gastric Cancer       Date:  2011-02-23       Impact factor: 7.370

Review 2.  Potential prognostic, diagnostic and therapeutic markers for human gastric cancer.

Authors:  Ming-Ming Tsai; Chia-Siu Wang; Chung-Ying Tsai; Hsiang-Cheng Chi; Yi-Hsin Tseng; Kwang-Huei Lin
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

3.  A cost-effectiveness analysis evaluating endoscopic surveillance for gastric cancer for populations with low to intermediate risk.

Authors:  Hui Jun Zhou; Yock Young Dan; Nasheen Naidoo; Shu Chuen Li; Khay Guan Yeoh
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.